Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Chronic myelogenous leukemia (CML)
Stage/Subtype:  chronic phase
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 78 for your search:
Start Over
Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors
Status: Active
Phase: Phase IV
Type: Treatment
Age: 18 and over
Trial IDs: B1871039, NCI-2014-02251, 2013-003250-25, NCT02228382
Dasatinib in Treating Patients with Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia
Status: Active
Phase: Phase IV
Type: Treatment
Age: 18 and over
Trial IDs: 2015-1040, NCI-2016-00362, NCT02689440
Transplantation of Ex Vivo Expanded, UCB-derived, Stem & Progenitor Cells vs. Unmanipulated UCB for HM Patients
Status: Not yet active
Phase: Phase III
Type: Treatment
Age: 16 to 60
Trial IDs: GC P#05.01.020, NCI-2016-01518, NCT02730299
Low-Dose Donor Bone Marrow Transplant in Treating Patients with Hematologic Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 montha to 70
Trial IDs: J1055, NCI-2011-00377, NCT01203722
Laboratory-Treated T Cells in Treating Patients with High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated with Donor Stem Cell Transplant
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: 2498.00, NCI-2011-03362, 2498, NCT01640301
Conventional and Regulatory T Cells in Treating Patients with Advanced Hematologic Malignancies Undergoing T Cell-Depleted Donor Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 13 to 60
Trial IDs: BMT236, NCI-2011-03025, NCT01660607
Inotuzumab Ozogamicin, Fludarabine Phosphate, Bendamustine Hydrochloride, and Rituximab before Donor Stem Cell Transplant in Treating Patients with Lymphoid Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 70
Trial IDs: 2012-0265, NCI-2012-02072, NCT01664910
Azacitidine in Treating Patients Undergoing Matched Unrelated Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: 201303012, NCI-2012-03105, NCT01747499
Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2012-0697, NCI-2013-00551, NCT01751425
AP1903 and Genetically Modified Donor T Cells after Donor Stem Cell Transplant in Treating Patients with Hematologic Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: 2012-0501, NCI-2013-01666, NCT01875237
A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: C41443/2057, NCI-2014-01456, 2013-005320-42, NCT02078960
Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients with Hematologic Malignancies Undergoing HSCT
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Prevention, Treatment
Age: 3 to 30
Trial IDs: PEDSBMT295, NCI-2016-00387, NCT02728700
A Phase 1/2, Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: INCB 57643-101, NCI-2016-01069, NCT02711137
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing an Umbilical Cord Blood Transplant for Hematologic Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 55 and under
Trial IDs: MT2005-10, NCI-2010-01444, 2005LS043, UMN-2005LS043, UMN-BMT-MT2005-10, UMN-MT2005-10, UMN-0507M71475, NCT00309842
Low-Dose Chemotherapy, Low-Dose Total-Body Irradiation, and Anti-Thymocyte Globulin Followed by Donor Bone Marrow Transplant in Treating Patients with Hematologic Malignancy or Kidney Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT2001-10, NCI-2010-02155, 0108M06725, 2001LS058, UMN-2001LS058, UMN-MT2001-10, NCT00303719
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation and Anti Thymocyte Globulin before Umbilical Cord Blood Transplantation in Treating Patients with Hematological Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT2005-02, NCI-2010-01415, 2005LS036, UMN-2005LS036, UMN-MT-2005-02, UMN-0507M70121, NCT00305682
Mismatched Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 65 and under
Trial IDs: IUCRO-0184, NCI-2011-02351, NCT00593554
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients with Hematologic Disease
Status: Active
Phase: Phase II
Type: Treatment
Age: 6 months to 45 years
Trial IDs: 2010.00, NCI-2010-00190, 2010, FHCRC 2010.00, Protocol 2010, 6095, NCT00719888
Donor Umbilical Cord Blood Transplant in Treating Patients with Hematologic Cancer
Status: Temporarily closed
Phase: Phase II
Type: Treatment
Age: Any age
Trial IDs: 2239.00, NCI-2009-01551, 2239, FHCRC-2239.00, 6722, FHCRC-IR-6722, NCT00723099
Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients with Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant
Status: Active
Phase: Phase II
Type: Treatment
Age: Under 65
Trial IDs: 2275.00, NCI-2010-00299, 2275, FHCRC-2275.00, IR-6800, NCT00796068
Immune Response after Stem Cell Transplant in HIV-Positive Patients with Hematologic Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 75 and under
Trial IDs: 2212.00, NCI-2009-01244, 2212, NCT00968630
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients with Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: Not specified
Trial IDs: 2206.00, NCI-2010-02222, NCT01251575
Two Step Donor Stem Cell Transplant in Treating Patients with High-Risk Hematological Malignancies
Status: Active
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 08D.85, NCI-2012-00407, 2007-61, NCT01315132
Reduced Intensity Donor Stem Cell Transplant in Treating Patients with Hematologic Malignancies
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 11D.247, NCI-2011-02345, 1795, 2011-31, NCT01384513
Start Over